Waldenstrom Macroglobulinemia - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 199 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Waldenstrom Macroglobulinemia - Pipeline Review, H2 2016, provides an overview of the Waldenstrom Macroglobulinemia (Oncology) pipeline landscape.

Waldenstrom macroglobulinemia (WM) is a type of non-Hodgkin lymphoma (NHL) that produces large amounts of an abnormal protein (called a macroglobulin). Risk factors include age, gender, family history, Hepatitis C and certain types of autoimmune disease, such as Sjogren syndrome, might be at higher risk for WM. Treatment includes stem cell transplantation, biological therapy, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Waldenstrom Macroglobulinemia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Waldenstrom Macroglobulinemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Waldenstrom Macroglobulinemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Waldenstrom Macroglobulinemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 16, 10, 1 and 3 respectively for Waldenstrom Macroglobulinemia.

Waldenstrom Macroglobulinemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Waldenstrom Macroglobulinemia (Oncology).
- The pipeline guide reviews pipeline therapeutics for Waldenstrom Macroglobulinemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Waldenstrom Macroglobulinemia (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Waldenstrom Macroglobulinemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Waldenstrom Macroglobulinemia (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Waldenstrom Macroglobulinemia (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Waldenstrom Macroglobulinemia (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Waldenstrom Macroglobulinemia Overview 9
Therapeutics Development 10
Pipeline Products for Waldenstrom Macroglobulinemia - Overview 10
Waldenstrom Macroglobulinemia - Therapeutics under Development by Companies 11
Waldenstrom Macroglobulinemia - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Waldenstrom Macroglobulinemia - Products under Development by Companies 16
Waldenstrom Macroglobulinemia - Companies Involved in Therapeutics Development 18
AbbVie Inc 18
Amgen Inc. 19
arGEN-X BV 20
Aurigene Discovery Technologies Limited 21
Bayer AG 22
BeiGene, Ltd. 23
Calithera Biosciences, Inc. 24
Celgene Corporation 25
Genentech, Inc. 26
Gilead Sciences, Inc. 27
Hutchison MediPharma Limited 28
IGF Oncology, LLC. 29
Incyte Corporation 30
Juno Therapeutics Inc. 31
Karyopharm Therapeutics, Inc. 32
Merck KGaA 33
Millennium Pharmaceuticals Inc 34
Novartis AG 35
Ono Pharmaceutical Co., Ltd. 36
Portola Pharmaceuticals, Inc. 37
Takeda Pharmaceutical Company Limited 38
Vivolux AB 39
Waldenstrom Macroglobulinemia - Therapeutics Assessment 40
Assessment by Monotherapy Products 40
Assessment by Combination Products 41
Assessment by Target 42
Assessment by Mechanism of Action 45
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 51
(dezapelisib + itacitinib adipate) - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
765IGF-MTX - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
acalabrutinib - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
alisertib - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
ARGX-110 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
BGB-3111 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
bortezomib - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
CA-4948 - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
carfilzomib - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
CB-839 - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
cerdulatinib - Drug Profile 97
Product Description 97
Mechanism Of Action 97
R&D Progress 97
copanlisib hydrochloride - Drug Profile 101
Product Description 101
Mechanism Of Action 101
R&D Progress 101
dezapelisib - Drug Profile 105
Product Description 105
Mechanism Of Action 105
R&D Progress 105
DI-B4 - Drug Profile 106
Product Description 106
Mechanism Of Action 106
R&D Progress 106
DTRMWXHS-12 - Drug Profile 107
Product Description 107
Mechanism Of Action 107
R&D Progress 107
entospletinib - Drug Profile 108
Product Description 108
Mechanism Of Action 108
R&D Progress 108
everolimus - Drug Profile 110
Product Description 110
Mechanism Of Action 110
R&D Progress 110
HMPL-523 - Drug Profile 122
Product Description 122
Mechanism Of Action 122
R&D Progress 122
INCB-50465 - Drug Profile 124
Product Description 124
Mechanism Of Action 124
R&D Progress 124
itacitinib adipate - Drug Profile 125
Product Description 125
Mechanism Of Action 125
R&D Progress 125
ixazomib citrate - Drug Profile 128
Product Description 128
Mechanism Of Action 128
R&D Progress 128
JCAR-015 - Drug Profile 137
Product Description 137
Mechanism Of Action 137
R&D Progress 137
lenalidomide - Drug Profile 142
Product Description 142
Mechanism Of Action 142
R&D Progress 142
M-7583 - Drug Profile 156
Product Description 156
Mechanism Of Action 156
R&D Progress 156
ONO-4059 - Drug Profile 157
Product Description 157
Mechanism Of Action 157
R&D Progress 157
oprozomib - Drug Profile 159
Product Description 159
Mechanism Of Action 159
R&D Progress 159
selinexor - Drug Profile 162
Product Description 162
Mechanism Of Action 162
R&D Progress 162
Small Molecules to Inhibit IRAK4 for Immunology and Oncology - Drug Profile 180
Product Description 180
Mechanism Of Action 180
R&D Progress 180
spebrutinib besylate - Drug Profile 181
Product Description 181
Mechanism Of Action 181
R&D Progress 181
TAK-659 - Drug Profile 183
Product Description 183
Mechanism Of Action 183
R&D Progress 183
venetoclax - Drug Profile 184
Product Description 184
Mechanism Of Action 184
R&D Progress 184
VLX-1570 - Drug Profile 194
Product Description 194
Mechanism Of Action 194
R&D Progress 194
Waldenstrom Macroglobulinemia - Dormant Projects 196
Waldenstrom Macroglobulinemia - Discontinued Products 197
Appendix 198
Methodology 198
Coverage 198
Secondary Research 198
Primary Research 198
Expert Panel Validation 198
Contact Us 198
Disclaimer 199

List of Tables

Number of Products under Development for Waldenstrom Macroglobulinemia, H2 2016 10
Number of Products under Development by Companies, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Development, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Development by Companies, H2 2016 (Contd..1) 17
Waldenstrom Macroglobulinemia - Pipeline by AbbVie Inc, H2 2016 18
Waldenstrom Macroglobulinemia - Pipeline by Amgen Inc., H2 2016 19
Waldenstrom Macroglobulinemia - Pipeline by arGEN-X BV, H2 2016 20
Waldenstrom Macroglobulinemia - Pipeline by Aurigene Discovery Technologies Limited, H2 2016 21
Waldenstrom Macroglobulinemia - Pipeline by Bayer AG, H2 2016 22
Waldenstrom Macroglobulinemia - Pipeline by BeiGene, Ltd., H2 2016 23
Waldenstrom Macroglobulinemia - Pipeline by Calithera Biosciences, Inc., H2 2016 24
Waldenstrom Macroglobulinemia - Pipeline by Celgene Corporation, H2 2016 25
Waldenstrom Macroglobulinemia - Pipeline by Genentech, Inc., H2 2016 26
Waldenstrom Macroglobulinemia - Pipeline by Gilead Sciences, Inc., H2 2016 27
Waldenstrom Macroglobulinemia - Pipeline by Hutchison MediPharma Limited, H2 2016 28
Waldenstrom Macroglobulinemia - Pipeline by IGF Oncology, LLC., H2 2016 29
Waldenstrom Macroglobulinemia - Pipeline by Incyte Corporation, H2 2016 30
Waldenstrom Macroglobulinemia - Pipeline by Juno Therapeutics Inc., H2 2016 31
Waldenstrom Macroglobulinemia - Pipeline by Karyopharm Therapeutics, Inc., H2 2016 32
Waldenstrom Macroglobulinemia - Pipeline by Merck KGaA, H2 2016 33
Waldenstrom Macroglobulinemia - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 34
Waldenstrom Macroglobulinemia - Pipeline by Novartis AG, H2 2016 35
Waldenstrom Macroglobulinemia - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 36
Waldenstrom Macroglobulinemia - Pipeline by Portola Pharmaceuticals, Inc., H2 2016 37
Waldenstrom Macroglobulinemia - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 38
Waldenstrom Macroglobulinemia - Pipeline by Vivolux AB, H2 2016 39
Assessment by Monotherapy Products, H2 2016 40
Assessment by Combination Products, H2 2016 41
Number of Products by Stage and Target, H2 2016 43
Number of Products by Stage and Mechanism of Action, H2 2016 46
Number of Products by Stage and Route of Administration, H2 2016 48
Number of Products by Stage and Molecule Type, H2 2016 50
Waldenstrom Macroglobulinemia - Dormant Projects, H2 2016 196
Waldenstrom Macroglobulinemia - Discontinued Products, H2 2016 197